• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Huber Martin H. Jr.

    5/6/26 4:00:12 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Huber Martin H. Jr.

    (Last)(First)(Middle)
    C/O ACTUATE THERAPEUTICS, INC.
    1751 RIVER RUN, SUITE 400

    (Street)
    FORT WORTH TEXAS 76107

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    ACTUATE THERAPEUTICS, INC. [ ACTU ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Non-Qualified Stock Options (1)05/01/2036Common Stock30,000$3D
    Explanation of Responses:
    1. 30,000 stock options were granted to Dr. Huber upon his appointment to the Board of Directors of Actuate Therapeutics, Inc., which option shall vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date.
    /s/ Paul Lytle, Attorney-in-Fact05/06/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $ACTU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    8/26/2025$20.00Buy
    B. Riley Securities
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    SEC Filings

    View All

    Actuate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/22/26 4:43:53 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Actuate Therapeutics Inc.

    S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/14/26 4:06:37 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Actuate Therapeutics Inc.

    10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/14/26 4:01:00 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Actuate Therapeutics with a new price target

    B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    8/26/25 8:17:26 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

    Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

    4/22/25 8:00:39 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

    - Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan - Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage bio

    6/1/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

    Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers

    5/11/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

    CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization. "We are pleased to welcome Marty to our Board of Directors. His dedication and expertise are going to prove invaluable to our mission,

    5/6/26 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zabrowski Dan

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:15:21 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Thomson Todd S

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:14:24 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sawhney Roger

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:10:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Actuate Therapeutics Inc.

    SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

    8/19/24 8:59:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Leadership Updates

    Live Leadership Updates

    View All

    Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

    Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers

    5/11/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

    CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization. "We are pleased to welcome Marty to our Board of Directors. His dedication and expertise are going to prove invaluable to our mission,

    5/6/26 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care